SBC Medical Group Holdings Incorporated (SBC) P/E Ratio History
Historical price-to-earnings valuation from 2023 to 2025
Loading P/E history...
SBC Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, SBC Medical Group Holdings Incorporated (SBC) trades at a price-to-earnings ratio of 6.7x, with a stock price of $3.21 and trailing twelve-month earnings per share of $0.42.
The current P/E is 62% below its 5-year average of 17.5x. Over the past five years, SBC's P/E has ranged from a low of 6.4x to a high of 35.6x, placing the current valuation at the 13th percentile of its historical range.
Compared to the Industrials sector median P/E of 25.5x, SBC trades at a 74% discount to its sector peers. The sector includes 413 companies with P/E ratios ranging from 0.0x to 185.3x.
Relative to the broader market, SBC trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SBC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SBC P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $882M | 9.7Lowest | 0.98 | -36% | |
| $161B | 57.6 | 2.65 | +23% | |
| $48B | 45.2 | 6.39 | -74% | |
| $17B | 30.5 | - | -25% | |
| $12B | 21.7 | 0.70Best | +423%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SBC Historical P/E Data (2023–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $4.34 | $0.42 | 10.3x | -41% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $4.64 | $0.33 | 14.3x | -18% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $3.19 | $0.50 | 6.4x | -63% |
| FY2024 Q4 | $5.56 | $0.49 | 11.4x | -35% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $7.97 | $0.58 | 13.8x | -21% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $13.07 | $0.64 | 20.5x | +17% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $12.70 | $0.46 | 27.6x | +58% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $10.77 | $0.30 | 35.6x | +104% |
Average P/E for displayed period: 17.5x
See SBC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SBC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SBC vs SPIR
Side-by-side business, growth, and profitability comparison vs Spire Global, Inc..
Start ComparisonSBC — Frequently Asked Questions
Quick answers to the most common questions about buying SBC stock.
Is SBC stock overvalued or undervalued?
SBC trades at 6.7x P/E, below its 5-year average of 17.5x. At the 13th percentile of historical range, the stock is priced at a discount to its own history.
How does SBC's valuation compare to peers?
SBC Medical Group Holdings Incorporated P/E of 6.7x compares to sector median of 25.5x. The discount suggests lower growth expectations or higher risk.
What is SBC's PEG ratio?
SBC PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2023-2025.